Stock listing
Annexin Pharmaceuticals Ab
Selected listing: Q910 · FWB · EUR · DE
Annexin Pharmaceuticals Ab (Frankfurt:Q910), Health Technology. Latest release Aug 20, 2026: Annexin Pharmaceuticals receives the International Nonproprietary…
- Ticker
- Frankfurt:Q910
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- Frankfurt
- Currency
- EUR
About Annexin Pharmaceuticals Ab
Annexin Pharmaceuticals Ab (ANNX) is listed on 6ix with investor news, events, company updates, and market data in one place. Follow the company page to track new releases, upcoming presentations, and the latest information available on 6ix.
Latest news from Annexin Pharmaceuticals Ab
Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV
August 20, 2026
Annexin's rights issue 98 percent subscribed
July 3, 2026
Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million
June 3, 2026
Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study
May 11, 2026
Annexin Pharmaceuticals : secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026
April 13, 2026
Research Annexin Pharmaceuticals Ab
Annexin Pharmaceuticals Ab company profile
View the public company page for Annexin Pharmaceuticals Ab on 6ix.
Annexin Pharmaceuticals Ab news
Read company news and market updates connected to Annexin Pharmaceuticals Ab.
Annexin Pharmaceuticals Ab investor events
Find investor webinars, events, and replay context for Annexin Pharmaceuticals Ab.